

## NONEXCLUSIVE LICENSE AGREEMENT

This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and \_\_\_\_\_ (“\*\*\*\*\*”), a corporation having a principal place of business at \_\_\_\_\_, is effective on the \_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_ (“Effective Date”).

### 1. BACKGROUND

Stanford has an assignment of an invention (insert marketing description here). It is entitled “\_\_\_\_\_,” was invented in the laboratory of \_\_\_\_\_, and is described in Stanford Docket \_\_\_\_\_. The invention was made in the course of research supported by the \_\_\_\_\_.

Stanford wants to have the invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit.

*(Special background of the particular license. Add a few details about the licensee and their business. If a trademark is involved, many other requirements must be stated.)*

### 2. DEFINITIONS

2.1 “**Change of Control**” means the following, as applied only to the entirety of that part of \*\*\*\*\*’s business that exercises all of the rights granted under this Agreement:

- (A) acquisition of ownership—directly or indirectly, beneficially or of record—by any person or group (within the meaning of the Exchange Act and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of \*\*\*\*\* representing more than 35% of either the aggregate ordinary voting power or the aggregate equity value represented by the issued and outstanding capital stock of \*\*\*\*\*; and/or
- (B) the sale of all or substantially all \*\*\*\*\*’s assets and/or business in one transaction or in a series of related transactions.

2.2 “**Licensed Field of Use**” means \_\_\_\_\_.

2.3 “**Licensed Patent**” means Stanford's U.S. Patent Application, Serial Number \_\_\_\_\_, filed \_\_\_\_\_, any foreign patent application corresponding thereto, and any divisional, continuation, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held

to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. "Licensed Patent" excludes any continuation-in-part (CIP) patent application or patent.

- 2.4 **"Licensed Product"** means a product or part of a product in the Licensed Field of Use:
- (A) the making, having made, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or
  - (B) which is made with, uses or incorporates any Technology.
- 2.5 **"Licensed Territory"** means \_\_\_\_\_.
- 2.6 **"Net Sales"** means:
- (A) all gross revenue derived by \*\*\*\*\*, its distributors or designees, from the sale, transfer or other disposition of Licensed Product to an end user
  - (B) minus 5%.
- 2.7 **"Stanford Indemnitees"** means Stanford, Stanford Health Care and Lucile Packard Children's Hospital at Stanford, and their respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers.
- 2.8 **"Technology"** means the additional information or materials listed in Appendix B that will be provided by Stanford to \*\*\*\*\*. Technology may or may not be confidential in nature.

### 3. GRANT

- 3.1 **Grant.** Subject to the terms and conditions of this Agreement, Stanford grants \*\*\*\*\* a license under the Licensed Patent and Technology in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory.
- 3.2 **Nonexclusivity.** The license is nonexclusive in the Licensed Field of Use beginning on (insert date) and ending when the last Licensed Patent expires.
- 3.3 **Specific Exclusion.** Stanford does not:
- (A) grant to \*\*\*\*\* any other licenses, implied or otherwise, to any patents or other rights of Stanford other than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent or Technology;
  - (B) commit to \*\*\*\*\* to bring suit against third parties for infringement; and

(C) agree to furnish to \*\*\*\*\* any technology or technological information other than the Technology or to provide \*\*\*\*\* with any assistance.

#### 4. **SUBLICENSING**

\*\*\*\*\* may not grant sublicenses.

#### 5. **GOVERNMENT RIGHTS**

This Agreement is subject to Title 35 Sections 200-204 of the United States Code. Among other things, these provisions provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the United States be “manufactured substantially in the United States.” \*\*\*\*\* will ensure all obligations of these provisions are met.

#### 6. **DILIGENCE**

6.1 **Milestones.** Because the invention is not yet commercially viable as of the Effective Date, \*\*\*\*\* will diligently develop, manufacture, and sell Licensed Product and will diligently develop markets for Licensed Product. In addition, \*\*\*\*\* will meet the following milestones and notify Stanford in writing as each milestone is met:

6.2 **Progress Report.** By March 1 of each year, \*\*\*\*\* will submit a written annual report to Stanford covering the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by \*\*\*\*\* toward meeting this Agreement’s diligence requirements. Each report will describe, where relevant: \*\*\*\*\*’s progress toward commercialization of Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Product, and significant corporate transactions involving Licensed Product. \*\*\*\*\* will specifically describe how each Licensed Product is related to each Licensed Patent.

6.3 **Clinical Trial Notice.** \*\*\*\*\* will notify the Stanford University Office of Technology Licensing prior to commencing any clinical trials at Stanford. If \*\*\*\*\* does not notify Stanford University Office of Technology Licensing at least 15 days prior to enrolling the first patient in a clinical trial at Stanford, \*\*\*\*\* agrees that it will pay \$50,000 to Stanford.

#### 7. **ROYALTIES**

7.1 **Issue Royalty.** \*\*\*\*\* will pay to Stanford a noncreditable, nonrefundable license issue royalty of \$\_\_\_\_\_ upon signing this Agreement.

- 7.2 **License Maintenance Fee.** Beginning \_\_\_\_\_ and each \_\_\_\_\_ thereafter, \*\*\*\*\* will pay Stanford a yearly license maintenance fee of \$\_\_\_\_\_. Yearly maintenance payments are nonrefundable.
- 7.3 **Milestone Payments.** \*\*\*\*\* will pay Stanford the following milestone payments:
- 7.4 **Earned Royalty.** In addition to the annual license maintenance fee, \*\*\*\*\* will pay Stanford earned royalties (Y%) on Net Sales as follows:
- 
- 7.5 **Earned Royalty if \*\*\*\*\* Challenges the Patent.** Notwithstanding the above, should \*\*\*\*\* bring an action seeking to invalidate any Licensed Patent, \*\*\*\*\* will pay royalties to Stanford at the rate of 2 x Y percent (2xY%) of the Net Sales of all Licensed Products sold during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by \*\*\*\*\* is both valid and infringed by a Licensed Product, \*\*\*\*\* will pay royalties at the rate of 3 x Y percent (3xY%) of the Net Sales of all Licensed Products sold.
- 7.6 **Obligation to Pay Royalties.** A royalty is due Stanford under this Agreement for any activity conducted under the licenses granted. For convenience's sake, the amount of that royalty is calculated using Net Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, \*\*\*\*\* will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products.
- 7.7 **No Escrow.** \*\*\*\*\* shall not pay royalties into any escrow or other similar account.
- 7.8 **Currency.** \*\*\*\*\* will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. \*\*\*\*\* will make royalty payments to Stanford in U.S. Dollars.
- 7.9 **Non-U.S. Taxes.** \*\*\*\*\* will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford.
- 7.10 **Interest.** Any payments not made when due will bear interest at the lower of (a) the Prime Rate published in the Wall Street Journal plus 200 basis points or (b) the maximum rate permitted by law.

## 8. ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING

- 8.1 **Quarterly Earned Royalty Payment and Report.** Beginning with the first sale of a Licensed Product by \*\*\*\*\* , \*\*\*\*\* will submit to Stanford a written report (even if there are no sales) and an earned royalty payment within 30 days after the end of each calendar quarter. This report will be in the form of Appendix A and will state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar

- quarter. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties are calculated. With each report \*\*\*\*\* will include any earned royalty payment due Stanford for the completed calendar quarter (as calculated under Section 7.4).
- 8.2 **No Refund.** In the event that a validity or non-infringement challenge of a Licensed Patent brought by \*\*\*\*\* is successful, \*\*\*\*\* will have no right to recoup any royalties paid before or during the period challenge.
- 8.3 **Termination Report.** \*\*\*\*\* will pay to Stanford all applicable royalties and submit to Stanford a written report within 90 days after the license terminates. \*\*\*\*\* will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold.
- 8.4 **Accounting.** \*\*\*\*\* will maintain records showing manufacture, importation, sale, and use of a Licensed Product for 7 years from the date of sale of that Licensed Product. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement.
- 8.5 **Audit by Stanford.** \*\*\*\*\* will allow Stanford or its designee to examine \*\*\*\*\*'s records to verify payments made by \*\*\*\*\* under this Agreement.
- 8.6 **Paying for Audit.** Stanford will pay for any audit done under Section 8.5. But if the audit reveals an underreporting of earned royalties due Stanford of 5% or more for the period being audited, \*\*\*\*\* will pay the audit costs.
- 8.7 **Self-audit.** \*\*\*\*\* will conduct an independent audit of sales and royalties at least every 2 years if annual sales of Licensed Product are over \$5,000,000. The audit will address, at a minimum, the amount of gross sales by or on behalf of \*\*\*\*\* during the audit period, the amount of funds owed to Stanford under this Agreement, and whether the amount owed has been paid to Stanford and is reflected in the records of \*\*\*\*\*. \*\*\*\*\* will submit the auditor's report promptly to Stanford upon completion. \*\*\*\*\* will pay for the entire cost of the audit.

## 9. EXCLUSIONS AND NEGATION OF WARRANTIES

- 9.1 **Negation of Warranties.** Stanford provides \*\*\*\*\* the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty:
- (A) of merchantability, of fitness for a particular purpose;
  - (B) of non-infringement; or

(C) arising out of any course of dealing.

9.2 **No Representation of Licensed Patent.** \*\*\*\*\* also acknowledges that Stanford does not represent or warrant:

(A) the validity or scope of any Licensed Patent; or

(B) that the exploitation of Licensed Patent or Technology will be successful.

## 10. INDEMNITY

10.1 **Indemnification.** \*\*\*\*\* will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind arising out of or related to the exercise of any rights granted \*\*\*\*\* under this Agreement or the breach of this Agreement by \*\*\*\*\*.

10.2 **No Indirect Liability.** Stanford is not liable for any special, consequential, lost profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise.

10.3 **Workers' Compensation.** \*\*\*\*\* will comply with all statutory workers' compensation and employers' liability requirements for activities performed under this Agreement.

10.4 **Insurance.** During the term of this Agreement, \*\*\*\*\* will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of \*\*\*\*\*. The insurance will provide minimum limits of liability of \$5,000,000 and will include all Stanford Indemnitees as additional insureds. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within 15 days of the Effective Date of this Agreement, \*\*\*\*\* will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. \*\*\*\*\* will provide to Stanford 30 days prior written notice of cancellation or material change to this insurance coverage. \*\*\*\*\* will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of \*\*\*\*\* will be primary coverage; insurance of Stanford Indemnitees will be excess and noncontributory.

## 11. EXPORT

\*\*\*\*\* and its affiliates will comply with all applicable United States laws and regulations controlling the export of licensed commodities and technical data relating to this Agreement. (For the purpose of this paragraph, "licensed commodities" means any article, material or supply but does not include information; and "technical data" means tangible or intangible technical information that is subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and

specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions regulations administered by the U.S. Department of the Treasury (31 CFR 500-600).

Among other things, these laws and regulations may prohibit or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. \*\*\*\*\* hereby gives written assurance that it will comply with, and will cause its affiliates to comply with all United States export control laws and regulations, that it understands it may be held responsible for any violation of such laws and regulations by itself or its affiliates, and that it will indemnify, defend and hold Stanford harmless for the consequences of any such violation.

## 12. MARKING

Before any Licensed Patent issues, \*\*\*\*\* will mark Licensed Product with the words "Patent Pending." Otherwise, \*\*\*\*\* will mark Licensed Product with the number of any issued Licensed Patent.

## 13. STANFORD NAMES AND MARKS

\*\*\*\*\* will not use (i) Stanford's name or other trademarks, (ii) the name or trademarks of any organization related to Stanford, or (iii) the name of any Stanford faculty member, employee, student or volunteer without the prior written consent of Stanford. Permission may be withheld at Stanford's sole discretion. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials, other promotional materials, presentations, case studies, reports, websites, application or software interfaces, and other electronic media.

## 14. PROTECTION OF PATENTS

### 14.1 Suspected Infringement. \*\*\*\*\* will promptly inform Stanford of any suspected infringement of a Licensed Patent by a third party.

## 15. TERMINATION

### 15.1 Termination by \*\*\*\*\*. \*\*\*\*\* may terminate this Agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination selected by \*\*\*\*\*.

### 15.2 Termination by Stanford.

(A) Stanford may also terminate this Agreement if \*\*\*\*\*:

- (1) is delinquent on any report or payment;

- (2) is not diligently developing and commercializing Licensed Product;
  - (3) misses a milestone described in Section 6.1;
  - (4) is in breach of any provision; or
  - (5) provides any false report.
- (B) Termination under this Section 15.2 will take effect 30 days after written notice by Stanford unless \*\*\*\*\* remedies the problem in that 30-day period.

**15.3 Surviving Provisions.** Surviving any termination or expiration are:

- (A) \*\*\*\*\*'s obligation to pay royalties accrued or accruable;
- (B) any claim of \*\*\*\*\* or Stanford, accrued or to accrue, because of any breach or default by the other party; and
- (C) the provisions of Articles 8, 9, and 10 and any other provision that by its nature is intended to survive.

**16. CHANGE OF CONTROL AND NON-ASSIGNABILITY**

**16.1 Change of Control.** If there is a Change of Control, \*\*\*\*\* will pay Stanford a \$\_\_\_\_\_ (“Change of Control Fee”) upon assignment of this Agreement per Section 16.2..

**16.2 Conditions of Assignment under Change of Control.** \*\*\*\*\* may assign this Agreement as part of a Change of Control upon prior and complete performance of the following conditions:

- (A) \*\*\*\*\* must give Stanford 30 days prior written notice of the assignment, including the new assignee’s contact information; and
- (B) the new assignee must agree in writing to Stanford to be bound by this Agreement; and
- (C) Stanford must have received the full Change of Control Fee.

**16.3 After the Assignment.** Upon a permitted assignment of this Agreement pursuant to Article 16, \*\*\*\*\* will be released of liability under this Agreement and the term “\*\*\*\*\*” in this Agreement will mean the assignee.

**16.4 Bankruptcy.** In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales of Licensed Product.



16.5 **Nonassignability of Agreement.** Except in conformity with Section 16.2 and Section 16.4, this Agreement is not assignable by \*\*\*\*\* under any other circumstances and any attempt to assign this Agreement by \*\*\*\*\* is null and void.

## 17. DISPUTE RESOLUTION

17.1 **Dispute Resolution by Arbitration.** Any dispute between the parties regarding any payments made or due under this Agreement will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures. The parties are not obligated to settle any other dispute that may arise under this Agreement by arbitration.

17.2 **Request for Arbitration.** Either party may request such arbitration. Stanford and \*\*\*\*\* will mutually agree in writing on a third-party arbitrator within 30 days of the arbitration request. The arbitrator's decision will be final and nonappealable and may be entered in any court having jurisdiction.

17.3 **Discovery.** The parties will be entitled to discovery as if the arbitration were a civil suit in the California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery.

17.4 **Place of Arbitration.** The arbitration will be held in Stanford, California unless the parties mutually agree in writing to another place.

17.5 **Patent Validity.** Any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum.

## 18. NOTICES

18.1 **Legal Action.** \*\*\*\*\* will provide written notice to Stanford at least three months prior to bringing an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. \*\*\*\*\* will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent.

18.2 **All Notices.** All notices under this Agreement are deemed fully given when written, addressed, and sent as follows:

All general notices to \*\*\*\*\* are mailed or emailed to:

Name: \_\_\_\_\_

Address: \_\_\_\_\_

Email: \_\_\_\_\_

All financial invoices to \*\*\*\*\* (i.e., accounting contact) are e-mailed to:

Name: \_\_\_\_\_

Email: \_\_\_\_\_

All progress report invoices to \*\*\*\*\* (i.e., technical contact) are e-mailed to:

Name: \_\_\_\_\_

Email: \_\_\_\_\_

All general notices to Stanford are e-mailed or mailed to:

Office of Technology Licensing  
3000 El Camino Real  
Building 5, Suite 300  
Palo Alto, CA 94306-2100  
info@otlmail.stanford.edu

All payments to Stanford are mailed to:

Stanford University  
Office of Technology Licensing  
Department #44439  
P.O. Box 44000  
San Francisco, CA 94144-4439

All progress reports to Stanford are e-mailed or mailed to:

Office of Technology Licensing  
3000 El Camino Real  
Building 5, Suite 300  
Palo Alto, CA 94306-2100  
info@otlmail.stanford.edu

Either party may change its address with written notice to the other party.

## 19. MISCELLANEOUS

19.1 **Waiver.** No term of this Agreement can be waived except by the written consent of the party waiving compliance.

- 19.2 **Choice of Law.** This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to agreements negotiated, executed, and performed within California.
- 19.3 **Entire Agreement.** The parties have read this Agreement and agree to be bound by its terms, and further agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof. The parties agree that this Agreement supersedes all previous and future purchase orders. This Agreement may not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party.
- 19.4 **Exclusive Forum.** The state and federal courts having jurisdiction over Stanford, California, United States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. \*\*\*\*\* submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over \*\*\*\*\* or constitutes an inconvenient or improper forum.
- 19.5 **Headings.** No headings in this Agreement affect its interpretation.
- 19.6 **Electronic Copy.** The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.

The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives.

**THE BOARD OF TRUSTEES OF THE LELAND  
STANFORD JUNIOR UNIVERSITY**

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_

**[INSERT FULL LEGAL NAME OF \*\*\*\*\* HERE]**

Signature: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Date: \_\_\_\_\_

## Appendix A – Sample Reporting Form

Stanford Docket No. S##-###

This report is provided pursuant to the license agreement between Stanford University and \*\*\*\*\*.

License Agreement Effective Date:

Name(s) of Licensed Products being reported:

Report Covering Period	
Yearly Maintenance Fee	\$
Number of Sublicenses Executed	
Gross Revenue	
U.S. Gross Revenue	\$
Non-U.S. Gross Revenue	\$
Net Sales	
U.S. Net Sales	\$
Non-U.S. Net Sales	\$
Royalty Calculation	
Royalty Subtotal	\$
Credit	\$
Royalty Due	\$

Comments:

## **Appendix B - Technology**